Vilanterol

Vilanterol (GW642444) is a long-acting β2 adrenergic receptor agonist. Vilanterol has pEC50 values for β2-AR, β1-AR, and β3-AR of 9.4, 6.4, and 6.1, respectively. Vilanterol selectively activates airway β2 adrenergic receptors, increases cAMP and thus relaxes bronchial smooth muscle. Vilanterol can be used in asthma research[3][5].

503068-34-6

GW642444

12352005

H302, H312, H332

Adrenergic Receptor

Reference compound

GPCR/G Protein; Neuronal Signaling

COVID-19-immunoregulation

Inflammation/Immunology; Endocrinology; Cancer

https://www.medchemexpress.com/Vilanterol.html

99.30

DMSO : 100 mg/mL (ultrasonic)

OC1=CC=C([C@@H](O)CNCCCCCCOCCOCC2=C(Cl)C=CC=C2Cl)C=C1CO

C24H33Cl2NO5

486.43

H302, H312, H332

[1]Slack RJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013 Jan;344 (1) :218-30|[2]Kempsford R, et al. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26 (2) :256-|[3]Harrell AW, et al. Metabolism and disposition of Vilanterol, a long-acting β (2) -adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41 (1) :89-100.|[4]Calzetta L, et al. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017 Jul 14. pii: S0014-2999 (17) 30470-3.|[5]Panayiotis A Procopiou, et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010 Jun 10. 53 (11) :4522-30.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

Reference compound1

Launched

β adrenergic receptor